Deuterated Caffeine Metabolic Stability

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Caffeine's pharmacokinetic profile leads to adverse effects such as rapid spikes and crashes in plasma concentration, causing physical and psychological issues like anxiety, insomnia, and addiction, due to its short half-life and rapid metabolism.

Innovation Solution

Deuterium-enriched caffeine (d9-caffeine) is developed to provide a longer half-life and sustained exposure, reducing the severity of these adverse effects by maintaining plasma levels and minimizing metabolite production.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If non-isotopically enriched caffeine is administered, then the desired stimulant effect is achieved, but rapid metabolism causes sharp spikes and crashes in plasma concentration leading to adverse effects

Engineering Contradiction:

Improvestability of plasma concentrationVSAvoidadverse effects from plasma concentration spikes and crashes

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies parameter changes by substituting hydrogen atoms with deuterium atoms in the caffeine molecule. This isotopic substitution alters the metabolic parameters of caffeine, specifically slowing down its metabolism by the cytochrome P450 enzyme system. The deuterium substitution changes the kinetic isotope effect, resulting in reduced metabolic rate and extended half-life, thereby preventing sharp plasma concentration spikes and crashes while maintaining the desired stimulant effect.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent creates a composite molecular structure by combining deuterium-enriched methyl groups with the caffeine core structure. This composite approach, where three methyl groups are specifically deuterated (forming d9-caffeine), modifies the overall pharmacokinetic properties without changing the fundamental molecular identity. The composite deuterated structure provides both the desired caffeine activity and improved metabolic stability.

Inventive Principle:

Principle #40Composite materials

2Duration of action of moving object

If caffeine is administered to achieve therapeutic effects, then the duration of action is short due to rapid clearance, but extending exposure time increases adverse effects

Engineering Contradiction:

Improvehalf-life of caffeineVSAvoidadverse effects from prolonged exposure

Core Design Contradiction:

Duration of action of moving objectVSObject-affected harmful factors

Solution Approach 1:

The deuterium substitution changes the metabolic clearance rate parameter of caffeine. By replacing hydrogen with deuterium at three methyl positions, the patent alters the enzyme-substrate interaction kinetics, reducing the metabolic rate and extending the half-life from approximately 5 hours to potentially 10 hours or more. This parameter change allows for prolonged therapeutic action without the need for repeated dosing, while the gradual decline in plasma concentration avoids the adverse effects associated with rapid clearance.

Inventive Principle:

Principle #35Parameter changes

3Duration of action of moving object

If high dose caffeine is used to extend the duration of effect, then the duration increases but the severity of plasma concentration spikes and adverse effects worsens

Engineering Contradiction:

Improveduration of stimulant effectVSAvoidseverity of adverse effects

Core Design Contradiction:

Duration of action of moving objectVSObject-generated harmful factors

Solution Approach 1:

The patent changes the metabolic clearance parameter through deuterium substitution, allowing for extended duration of action at lower doses. The slowed metabolism of d9-caffeine means that lower doses can achieve and maintain therapeutic plasma concentrations for longer periods, avoiding the need for high doses that would otherwise be required to extend duration. This parameter modification decouples the relationship between dose and duration, enabling prolonged effect without proportional increase in adverse effects.

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

d9-caffeine offers reduced side effects, increased duration of action, and improved patient compliance by maintaining energy and wakefulness without the sharp drops associated with natural caffeine, making it suitable for various applications including energy enhancement and disease treatment.

Implementation Method 1

Caffeine ingestion results in a high maximal plasma concentration (plasma Cmax), a short time of maximal plasma concentration (Tmax) after ingestion, short half-life (t1/2), and rapid clearance, mainly by hepatic cytochrome P450 (CYP450) demethylation to afford paraxanthine, theobromine, and theophylline.

Methodology Applied

Scientific EffectCytochrome P450 demethylation: Enzyme

Data Source

PatentUS12194046B2D9-caffeine compositions and uses thereof

Publication Date: 2025.01.14 LENNHAM PHARMACEUTICALS INC

AI summary

Provided herein are compositions (e.g., pharmaceutical compositions, nutraceutical compositions, foods, beverages, cosmetic compositions, nutritional supplements) comprising d9-caffeine. The provided compositions may be useful for treating and/or preventing various diseases and conditions, such as obesity, causing weight loss, increasing metabolic rate, reducing appetite, increasing energy expenditure, decreasing daytime sleepiness, increasing urine output, increasing sodium excretion, reducing edema, a pain disorder, apnea, hypotension, an encephalopathy, a neurological or psychiatric disorder, and an inflammatory disorder.